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Mutations of the Mitochondrial-tRNA Modifier MTO1
Cause Hypertrophic Cardiomyopathy and Lactic Acidosis
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Dysfunction of mitochondrial respiration is an increasingly recognized cause of isolated hypertrophic cardiomyopathy. To gain insight
into the genetic origin of this condition, we used next-generation exome sequencing to identify mutations in MTO1, which encodes
mitochondrial translation optimization 1. Two affected siblings carried a maternal c.1858dup (p.Arg620Lysfs*8) frameshift and
a paternal c.1282G>A (p.Ala428Thr) missense mutation. A third unrelated individual was homozygous for the latter change. In both
humans and yeast, MTO1 increases the accuracy and efficiency of mtDNA translation by catalyzing the 5-carboxymethylaminomethy-
lation of the wobble uridine base in threemitochondrial tRNAs (mt-tRNAs). Accordingly, mutantmuscle and fibroblasts showed variably
combined reduction in mtDNA-dependent respiratory chain activities. Reduced respiration in mutant cells was corrected by expressing
a wild-typeMTO1 cDNA. Conversely, defective respiration of a yeastmto1D strain failed to be corrected by anMto1Pro622* variant, equiv-
alent to human MTO1Arg620Lysfs*8, whereas incomplete correction was achieved by an Mto1Ala431Thr variant, corresponding to human
MTO1Ala428Thr. The respiratory yeast phenotype was dramatically worsened in stress conditions and in the presence of a paromomy-
cin-resistant (PR) mitochondrial rRNA mutation. Lastly, in vivo mtDNA translation was impaired in the mutant yeast strains.Infantile hypertrophic cardiomyopathy and lactic acidosis
are key clinical features in an increasing number of mito-
chondrial disorders associated with severe dysfunction of
oxidative phosphorylation (OXPHOS), the main energy-
supply pathway of cardiomyocytes. The advent of exome
analysis by next-generation sequencing (NGS) technology
has begun to elucidate the genetic defects underpinning
this condition. Recently, exome-NGS allowed us to iden-
tify mutations in ACAD9 (MIM 611103), which encodes
mitochondrial flavin adenine dinucleotide (FAD)-depen-
dent acyl-coenzyme-A dehydrogenase 9, in several
children affected by early-onset, isolated hypertrophic
cardiomyopathy (MIM 611126).1 The role of ACAD9
seems to be marginal for fatty-acid beta oxidation, but
essential for the assembly of mitochondrial respiratory
chain (MRC) complex I (CI).1–3 Another recent example
is mutations in AGK (MIM 610345), which encodes acyl-
glycerol kinase, a mitochondrial enzyme involved in the
biosynthesis of cardiolipin; these mutations are respon-
sible for hypertrophic cardiomyopathy and congenital
cataracts (Sengers syndrome [MIM 212350]).4 Cardiolipin
is an essential component of the lipid milieu of the inner
mitochondrial membrane that participates in the integrity
and optimization of the activity of both the MRC
complexes and the skeletal-muscle- and heart-specific
solute carrier family 25 (adenine nucleotide translocator
1), SLC25A4. Likewise, rare, recessive mutations in
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The Americmyopathy (MIM 192600), and yet another X-linked reces-
sive condition, Barth syndrome, hallmarked by severe
mitochondrial cardiomyopathy (MIM 302060), is caused
by a mutation in TAZ (MIM 300394), which encodes
Tafazzin, an acyl-transferase, specific to cardiolipin, that
optimizes its fatty-acid composition to the structural and
functional needs of the MRC. Other children with severe,
isolated cardiomyopathy and lactic acidosis harbor reces-
sive mutations in TMEM70 (MIM 612418), which encodes
a bona fide assembly factor of MRC CV (ATP-synthase).5
Syndromic cardiomyopathy, in combination with enceph-
alopathy, myopathy, or both, is also associated with
a number of mutations of mtDNA or nuclear genes that
affect MRC activities.6 Nevertheless, a substantial propor-
tion of cases characterized by OXPHOS-related severe
hypertrophic cardiomyopathy remains genetically undiag-
nosed.
Through exome-NGS analysis of a selected cohort of
affected individuals, we identified pathogenic mutations
in MTO1 (NC_000006.11), which encodes an enzyme
involved in posttranscriptional modification of mitochon-
drial tRNAs (mt-tRNAs).
Affected person 1 (Pt1) was the first child of nonconsan-
guineous, healthy parents from northern Italy. He was
born at 29 weeks of gestational age, by caesarean section
because of oligohydramnios and reduced fetal growth.
His birth weight was 790 g, his length was 34.5 cm, and
his head circumference was 25.5 cm. Immediately afterura a Carattere Scientifico) Istituto Neurologico ‘‘Carlo Besta,’’ 20126 Milan,
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Table 1. Biochemical Analysis of OXPHOS Activities
Muscle CSa CI SDH CII CIII CIV CV
Ct values 80–210 13–24 10.7–17,4 15–28 60–100 120–220 130–280
Pt2 73 5 (27) 16.8 (120) 28.7 (133) 95.3 (119) 46.5 (27) 351 (171)
Pt3 (3 mo) 209 2.2 (12) 13.1 (93) nd b nd b 51 (30) nd
Pt3 (17 yr) 147 1.3 (7) 13.6 (97) 26.3 (122) 75 (94) 59 (35) 144 (70)
Fibroblasts CSa CI SDH CII CIII CIV CV
Ct values 100–200 10.7–26 6.5–14,3 8.6–18,4 70–120 70–125 65–113
Pt1 160 12.5 (68) 14.3 (137) 24.6 (182) 57 (60) 55 (56) 93 (104)
Pt2 101 10.1 (55) 11 (105) 30.3 (224) 92 (97) 111 (114) 126 (141)
Pt1 þ riboflavin 142 11.6 (63) nd nd 53 (56) 62 (64) nd
Pt2 þ riboflavin 82 6.5 (35) nd nd 71 (75) 76 (78) nd
nd, not determined; þ riboflavin, fibroblasts cultured for 1 week with Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 5.3 mM riboflavin.
Parentheses indicate percentages relative to the mean control (Ct) value. Values below the control range are reported in bold. All enzymatic activities are normal-
ized for CS activity. Two muscle biopsies were analyzed in Pt3; the first taken at 3 months of age (3 mo) and the second at 17 years of age (17 yr).
aCitrate synthase (CS) activity, expressed as nmol min1 mg1.
bIn Pt3 muscle, the ratio CIIþCIII (succinate cytochrome c reductase)/CS was 16.6 (105% of the Ct value; normal range 12.2–19.4).birth he had an episode of metabolic failure with severe
hypoglycemia (25 mg%), metabolic acidosis (pH 7.17,
base excess [BE] 11.7 mEq/l), and high blood lactate
(13 mM, normal values [nv] < 2.0). In the subsequent
days, blood glucose levels were corrected by the infusion
of dextrose, whereas plasma lactate remained high (10–
15 mM), with mild hyperammonemia (195 mg%, nv <
80). Electroencephalogram (EEG) and cerebral echography
results were normal, as were those of a liver and spleen
ultrasound examination. Interventricular septum hyper-
trophy was detected on the 15th day (6.4 mm, nv < 3).
He died on the 19th day of sudden bradycardia unrespon-
sive to resuscitation procedures. MRC activities in digi-
tonin-permeabilized skin fibroblasts showed a reduction
of CIII normalized to citrate synthase (CS) (CIII/CS ¼
60% of the controls’ mean) and of CIV/CS (56%), whereas
the other activities were within the controls’ range
(Table 1). Sequence analysis of muscle mtDNA revealed
a normal H1t haplogroup common in Europeans.
Affected person 2 (Pt2), our index case, was the younger
sister of Pt1. She also was born at 36 weeks of gestational
age by caesarean section because of oligohydramnios
and reduced fetal growth. Her birth weight was 1,380 g,
her length was 42 cm, and her head circumference was
30 cm. At birth, she was mildly hypotonic and had severe
metabolic acidosis (pH 7.21, BE 13 mEq/l), with high
blood lactate (17.9 mM). She was immediately started on
biotin (10 mg per day), Coenzyme Q10 (14 mg per day),
thiamine (150 mg per day), and dichloroacetate (DCA;
30 mg per day). Plasma lactate stabilized to values between
6 and 10 mM. EEG and brain ultrasound results were
normal. On the seventh day, she became tachycardic.
Heart ultrasound findings were normal until the 38th
day, when septum hypertrophy (7 mm, nv 3.5) and left-
ventricular-wall hypertrophy (6 mm, nv 4) were found.1080 The American Journal of Human Genetics 90, 1079–1087, JuneShe died on the 40th day of sudden bradycardia unrespon-
sive to resuscitation procedures. An autopsy showed
the presence of cardiomegaly, pleural effusion, and ascites.
Biochemical assays, performed on the 8003 g supernatant
from the homogenate of a muscle biopsy, showed a
reduction of the ratios of CI/CS and CIV/CS. MRC activi-
ties in digitonin-permeabilized fibroblasts showed only
the reduction of CI/CS (Table 1). Sequence analysis of
muscle mtDNA revealed a normal H1t haplogroup, and
Sanger sequence analysis of ACAD9, TMEM70, NDUFS2
(MIM 602985), and NDUFV2 (MIM 600532) showed no
mutation.
Affected person 3 (Pt3), a boy, was born at term to report-
edly nonconsanguineous, healthy parents originating
from a small village in the alpine region of northeastern
Italy. His initial clinical history has been reported else-
where.7 At the age of 1 month, he developed hyperpnea,
difficulty feeding, weakness, and a lack of ocular fixation.
His liver was 5 cm below the costal margin; he had severe
metabolic acidosis, with high blood lactate (5.5 mM, nv <
2.0). An electrocardiogram (ECG) showed signs of
ischemia, and a cardiac ultrasound examination revealed
marked hypertrophic cardiomyopathy, particularly
affecting the posterior wall of the left ventricle (8.5 mm,
nv 4), reduced left-ventricular function, and mild pericar-
dial effusion. Biochemical assays on the 8003 g superna-
tant of the homogenate from a muscle biopsy taken at
3 months of age revealed severe reduction of CI/CS (12%
of the controls’ mean) and CIV/CS (30%) ratios, whereas
succinate dehydrogenase (SDH)/CS and CIIþIII/CS ratios
as well as CS (Table 1) and pyruvate dehydrogenase activi-
ties were normal. DCA treatment resulted in marked
improvement of both metabolic acidosis and cardiomyop-
athy. After 9 months of DCA therapy, a cardiac ultrasound
examination showed a normal-sized heart, with normal8, 2012
left-ventricular-wall thickness (5 mm) and function (ejec-
tion fraction 76%, systolic fraction 43%) and low blood
lactate values, ranging from 1.6 to 3.1 mM. During his first
years of life, Pt3 had no severe episode of metabolic
acidosis, even if plasma lactate remained moderately
high, ranging from 2.5 to 4 mM. His growth rate has
been normal, with good neurological development and
a normal brain anatomy, according to magnetic resonance
imaging. He was put on a permanent treatment of DCA
(200 mg per day), carnitine (1 g per day), and CoQ10
(100 mg per day). Because of the possible side effects of
DCA, he was monitored regularly through the evaluation
of visual and brainstem auditory evoked potentials as
well as electromyography and nerve conduction velocities.
At the age of 7 years, ultrasound examination showed
a normal systolic ejection fraction in spite of a slight dila-
tion of the left-ventricular chamber. At 12 years, DCA
was stopped because of normalization of plasma lactate.
A second muscle biopsy, taken at 17 years, again showed
severe reduction of CI/CS (7% of the controls’ mean) and
CIV/CS (35%), whereas the other MRC activities were
normal (Table 1). Sequence analysis of mtDNA showed
a normal H2 haplogroup. He is now 19 years old with
a normal scholastic performance. A recent ultrasound
examination revealed the presence of hypertrophic
cardiomyopathy with an ejection fraction of 60%. An
ECG showed sinus bradycardia (45 beats per min) but
a Holter ECG was otherwise normal. A neurological exam-
ination was normal, except for a reduction of skills in the
execution of fine movements, more evident in the left
hand. Ophthalmoscopic examination showed moderate
bilateral optic atrophy. Visual-evoked potential showed
an increased P100 latency, more marked in the left eye.
Electromyography and nerve-conduction velocity were
normal.
Informed consent for participation in this study was
obtained from the parents of all individuals involved, in
agreement with the Declaration of Helsinki and approved
by the ethics committees of the Fondazione IRCCS
(Istituto di Ricovero e Cura a Carattere Scientifico) Istituto
Neurologico (Milan, Italy).
We first carried out exome-NGS in the index case. The
DNA extracted from fibroblasts was processed with the
SureSelect Human All Exon 50 Mb kit (Agilent) and subse-
quently sequenced as 76 base-pair (bp) paired-end runs to
an average coverage of 1203, corresponding to 9–12 Gb of
sequence data. Read alignment was performedwith the use
of the Burrows-Wheeler Aligner (version 0.5.8) applied to
the human genome assembly hg19. Single-nucleotide
variants and small insertions and deletions were detected
with SAMtools (version 0.1.7). Given that mitochondrial
disorders are rare conditions, we excluded variants with
a frequency > 0.2% in ‘‘in house’’ control exomes and
public databases. Assuming an autosomal-recessive
mode of inheritance, we searched for homozygous or
compound-heterozygous variants, which were filtered
against (1) variants known to be associated with MRCThe Americdefects and (2) novel homozygous or compound-heterozy-
gous variants affecting genes that encode mitochondrial
proteins listed in MitoP2 (score > 0.5). This filtering proce-
dure (Table S1 available online) revealed that our index
case was compoundheterozygous for mutations in MTO1:
a maternal c.1858dup (p.Arg620Lysfs*8) and a paternal
c.1282G>A (p.Ala428Thr) (Figure 1A). The same muta-
tions were also found in her affected brother.
The frameshift mutation is predicted to introduce a stop
codon after an aberrant sequence of seven amino acids (aa)
(Figure S1), causing the loss of the C-terminal 73 aa resi-
dues (z10% of the protein size); the missense mutation
affects an amino-acid residue, Ala428, which is invariant
in all available animal, plant, and yeast species, including
Saccharomyces cerevisiae (Figures S2A and S2B). In addition,
the Ala428Thr change scored very highly for likelihood to
be deleterious according to ad-hoc softwares for pathoge-
nicity prediction (deleterious for Polyphen2: p ¼ 0.999;
Panther: 0.88041; MutPred: 0.903). The exome variant
server (EVS) of the NHLBI GO Exome Sequencing Project
reports a frequency of 0.028% (2/7,020) in the American
population of European origin for the c.1282G>A change,
whereas the c.1858dup change was not present in the data-
base. We also excluded the missense mutation from our
exome database, which contains 973 genomes from
Europeans (¼1,946 alleles), and from a database of 300
alleles from consecutive control DNA samples from
subjects originating from northern Italy.
To evaluate a possible influence of the two mutations on
the stability of the transcript, we extracted mRNA from
mutant fibroblasts of affected individuals 1 and 2 and
retrotranscribed it into cDNA. Quantitative real-time PCR
showed that the content of mutant MTO1 transcripts
was similar to that of wild-type (WT) control samples
(Figure 1B), and sequence analysis revealed the presence
of comparable amounts of either mutant transcript (data
not shown), indicating no RNA decay.
Next, we analyzed MTO1 on isolated mitochondria
and on total cell lysates obtained from both mutant and
control immortalized fibroblasts, using a polyclonal
MTO1 antibody (Proteintech). MTO1 is predicted by
bioinformatic tools (MitoProt, TargetP) to be imported
inside mitochondria after the cleavage of a 25-aa-long
mitochondrial targeting sequence. We synthesized the
polypeptides corresponding to the precursor, the mature
WT, and the mature p.Arg620Lysfs*8 truncated MTO1
species (TNT Transcription-Translation System kit, Prom-
ega). After performing SDS-polyacrylamide electrophoresis
and electroblotting, we immunovisualized a band reacting
with an MTO1 antibody in mitochondria (Figure 1C)
and in fibroblast lysates (Figure S3). This band, which
comigrates with a band corresponding to the 74 kDa full-
length, mature in-vitro-synthesized MTO1 polypeptide
(NM_012123, NP_036255), was markedly increased in
MTO1-overexpressing fibroblasts (Figure S3). In mutant
mitochondria, the amount of the 74 kDa protein was
clearly reduced, whereas an additional band was detected,an Journal of Human Genetics 90, 1079–1087, June 8, 2012 1081
Figure 1. MTO1 Mutations
(A) Electropherograms of MTO1 of Pt2 showing the c.1282G>A (left) and c.1858dup (right), both in heterozygosis.
(B) Real-time PCR on retrotranscribed cDNA from fibroblasts of individuals 1 (P1) and 2 (P2). The amount of MTO1 transcript (normal-
ized to GAPDH levels) is comparable in mutant versus WT control samples (Ct), indicating no mRNA decay. Data are represented as
mean5 SD.
(C) Western-blot analysis of MTO1. Top: schematic representation of the precursor WT MTO1 (isoform a), its mature species after
cleavage of a predicted 25 aa mitochondrial targeting sequence in the N terminus, and the mature p.Arg620Lysfs*8 mutant species.
Bottom: Western-blot analysis on isolated mitochondria. Retic.: reticulocyte lysate used for in-vitro protein synthesis; Prec.: in-vitro-
translated 77 kDaMTO1 precursor protein (green arrowhead); Ct: isolatedmitochondria from control fibroblasts; P2: isolatedmitochon-
dria from individual 2 fibroblasts; fs*8: in-vitro-translated 67 kDa mature protein carrying the truncating p.Arg620Lysfs*8 variant
(red arrowhead); Mat.: in-vitro-translated 74 kDa WT mature MTO1 (black arrowhead). A faint crossreacting band is visualized in mt
P2 sample (red asterisk), corresponding to the mature p.Arg620Lysfs*8 truncated protein. An unspecific signal is present in mt samples
(gray asterisks). The position of the 72 kDa molecular weight marker protein is also indicated. SDHA was used as loading control.
(D) MRR measured in immortalized fibroblasts from Pt 2, in naive condition (P2) or overexpressing MTO1 (P2þMTO1), and in control
subjects (Ct1, Ct2). MRR values are expressed as pMolesO2/min/cells. Data are represented as mean5 SD. Two-tail, unpaired Student’s
t test was applied for statistical significance. ***: p < 0.001.with the same electrophoretic mobility of the in-vitro-
synthesized mature p.Arg620Lysfs*8 MTO1 species, pre-
dicted to have a molecular weight ofz67 kDa. This result
suggests that the p.Arg620Lysfs*8 truncated MTO1 is rela-
tively stable (Figure 1C).
In order to prove the causative role of the MTO1 variants
found in the affected siblings of family 1, we first tested
whether the expression of WT MTO1 cDNA could rescue
the biochemical phenotype of mutant cells. Given that
the MRC defects in Pt1 and Pt2 fibroblasts were relatively
mild and variable, we immortalized the Pt2 fibroblasts
using pBABE-puro SV40 and evaluated the oxygen
consumption through microscale oxygraphy (Seahorse
Bioscience XF-96). This assay, which depends upon and1082 The American Journal of Human Genetics 90, 1079–1087, Junereflects the cumulative proficiency of the whole set of
MRC complexes, is more sensitive than individual assays
of each complex.8 We demonstrated a clear reduction of
the maximal respiration rate (MRR) in immortalized Pt2
cells compared to immortalized control fibroblasts, which
returned to normal after transduction with a MTO1WT-ex-
pressing lentivirus (pLenti6 Gateway Vector kit, Invitro-
gen) (Figures 1E and S3). This result indicates a pathogenic
role of the MTO1 variants found in Pt2 mutant cells.
Second, we sequenced the exons and exon-intron
boundaries of MTO1 in DNA samples from 17 individuals
with early-onset hypertrophic cardiomyopathy, lactic
acidosis, and defective MRC activities. We found a
single individual, Pt3, homozygous for the c.1282G>A8, 2012
Figure 2. Respiratory Phenotypes of Yeast
Mutant Strains
(A and B) Respiratory activity of yeast mto1D
strains transformed with MTO1WT recombinant
vector, (empty) vector, and mto1Ala431Thrand
mto1Pro622* recombinant vectors at 28C (A) and
37C (B). Respiratory rates were normalized to
the WT strain, for which the respiratory rate
was 38.2 nmol min1 mg1 at 28C and
28.9 nmol min1 mg1 at 37C. Values are the
mean of at least three independent experiments.
Two-tail, unpaired t test was applied for statistical
significance. *: p < 0.05; **p < 0.01; ***: p <
0.001. Data are represented as mean5 SD.(p.Ala428Thr) mutation, identical to that found in the
paternal allele of family 1.
In both yeast and humans, MTO1 encodes the enzyme
that catalyzes the 5-carboxymethylaminomethylation
(mnm5s2U34) of the wobble uridine base in mt-tRNAGln,
mt-tRNAGlu, andmt-tRNALys. 9 This modification is usually
coupled to the 2-thiolation of the same uridine moiety,
a reaction catalyzed by 2-thiouridylase, encoded by
MTO2 (TRMU in humans [MIM 610230]); both these post-
transcriptional modifications increase accuracy and effi-
ciency of mtDNA translation.10 In order to further test
the pathogenic role of the MTO1 mutations, we used the
yeast Saccharomyces cerevisiae. We first showed that the
absence of MTO1 (mto1D) was associated with decreased
respiration rate in yeast incubated at 28C (Figure 2A).
Second, we demonstrated that this phenotype failed to
be corrected by expression of a recombinant yeast MTO1
cDNA encoding protein variant Pro622*, corresponding
to the human Arg620Lysfs*8 change (Figure S2, Table
S2). This result suggests that, although present in human
mitochondria, the Arg620Lysfs*8 MTO1 variant is func-
tionally inactive. The respiratory phenotype of the
mto1D strain was only partially corrected by expression
of a yeast recombinant MTO1 encoding protein variant
Ala431Thr, corresponding to the human Ala428Thr
change (Figure S2, Table S2), whereas the expression of
yeastMTO1WT led to full recovery (Figure 2A). These results
were qualitatively unchanged, but dramatically amplified,
in experiments carried out under temperature-induced
stress conditions; i.e., at 37C (Figure 2B). However,
neither the growth of mto1D nor that of mto1Pro622* or
mto1Ala431Thr strains on oxidative carbon sources was
significantly impaired. The OXPHOS-negative growth
phenotype of mto1 mutants is in fact contingent on the
presence of a C>G transversion at nucleotide 1477 of the
15S rRNA in mtDNA.11 The mutation disrupts the C1477-
G1583 base pairing in a functionally relevant hairpin struc-
ture, which is part of the decoding site (site A) of the ribo-The American Journal of Humsome, where the codon-anticodon recogni-
tion occurs.12 This mutation confers
resistance to the antibiotic paromomycin
(Figure 3) by destabilizing the hairpin and
results in a synthetic phenotype withMTO1 disruption,11 most likely due to impaired interac-
tion between unprocessed MTO1-dependent mt-tRNAs
with ribosomal site A.13
The normal human mitochondrial 12S rRNA contains
a hairpin structure that corresponds to the paromomy-
cin-resistant (PR) variant in yeast, because C1494 and
A1555, which are equivalent to yeast C1477 and G1583,
cannot form a pair. Incidentally, the well-known patho-
genic m.1555A>G mutation of human mtDNA as well as
the m.1494C>T can establish a C1494-G1555 pairing or the
equivalent U1494-A1555 pairing, respectively, both of which
increase the length of the hairpin structure, thus letting
paromomycin (and other aminoglycosides) bind to site A
(Figure 3).14 As a consequence, the m.1555A>G and
m.1494C>T both confer aminoglycoside susceptibility to
human mtDNA, being associated with a specific pheno-
type, aminoglycoside-induced nonsyndromic deafness
(MIM 580000).15,16
Given that human WT 12S RNA site A is structurally
similar to the yeast PR variant of the 15S RNA site A
(Figure 3), we extended our complementation analysis to
a m.1477C>G mutant PR yeast strain.
We showed that, in contrast to the mto1D paromomy-
cin-sensitive (PS) strain, the mto1D PR strain was unable
to grow on oxidative carbon sources such as glycerol
(Figure 4A). The oxidative growth remained abolished
with the expression of a cDNA encoding Mto1Pro622*,
clearly reduced with the expression of a cDNA encoding
Mto1Ala431Thr, and fully restored with the expression of
a cDNA encoding MTO1WT(Figure 4A).
Likewise, the respiration rate, which was nearly abol-
ished in themto1D PR strain, was not corrected by transfor-
mation with the Mto1Pro622*-encoding cDNA and only
partially corrected by the Mto1Ala431Thr-encoding cDNA,
in contrast to the full recovery obtained by expressing
a MTO1WT cDNA (Figure 4B). We observed no difference
between MTO1WT and mto1 mutant strains in the
frequency of ‘‘petite’’ colonies; i.e., respiration-defectivean Genetics 90, 1079–1087, June 8, 2012 1083
Figure 3. A-Site Structures of Yeast 15S and Human 12S rRNAs
Secondary structure of site A of the WT yeast strain 15S rRNA, of the PR yeast strain 15S rRNA, of the WT human 12S rRNA, and of
the mutant human 12S rRNA—the last two carrying either the 1555G or the 1494T mtDNA mutation, both associated with PS. The
pairing of 1477–1583 nucleotides in WT yeast rRNA corresponds to that of 1494-1555 nucleotides in mutant human rRNA and confers
aminoglycoside susceptibility.clones caused by large deletions or loss of mtDNA (data not
shown), which indicates that mutations in MTO1 did not
affect mtDNA stability.
Analysis in yeast clearly shows that while both muta-
tions are detrimental for respiratory activity, the delete-
rious effects of the Pro622* protein variant is more severe
than the Ala431Thr replacement. These results are concor-
dant with the clinical phenotype associated with the
equivalent mutations in humans: the third affected indi-
vidual, homozygous for the MTO1 mutation encoding
the Ala428Thr protein variant, equivalent to the yeast
Ala431Thr, is now 19 years old, and in relatively well-
compensated condition, whereas individuals 1 and 2,
who were compound heterozygous for the MTO1 muta-
tions encoding the Ala428Thr and Arg620Lysfs*8 muta-
tions, the latter being equivalent to the yeast Pro622*,
died a few days after birth of intractable congestive heart
failure and severe lactic acidosis.
MTO1 encodes a FAD-containing enzyme involved in
posttranscriptional modification of specific mt-tRNAs,
thus contributing to the optimization of mtDNA-depen-
dent protein synthesis. However, similar to a recent report
on the effects on in-vivo mtDNA translation of TRMU
(MTO2) mutations,17 we failed to show consistent alter-
ations of mtDNA-dependent protein synthesis in Pt2
mutant fibroblasts assayed in standard conditions18
(Figure S4). Hence, we evaluated the effect on mtDNA
translation of the expression of cDNAs encoding the
Mto1Pro622* and Mto1Ala431Thr variants, versus MTO1WT,
in the highly sensitive mto1D PR yeast model.19 Interest-
ingly, the mtDNA protein synthesis in the mto1D strain
expressing a cDNA encoding Mto1Pro622* was markedly
reduced, particularly for cytochrome c oxidase (Cox)
subunits 1 and 2 and for cytochrome b, similar to, albeit1084 The American Journal of Human Genetics 90, 1079–1087, Junelesser than, the null mto1D strain. The mtDNA translation
pattern in the mto1D strain expressing a cDNA encoding
Mto1Ala431Thr was similar to that of the MTO1WT strain,
although some bands, such as those corresponding to
the Var1 and adenosine triphosphatase (ATPase) 6 poly-
peptides, were slightly reduced in the mutant versus WT
strains (Figure 5). As expected, these results confirm that
the effects of the Mto1Pro622* truncating mutation are
more deleterious on mtDNA translation than those of the
Mto1Ala431Thr missense mutation, in agreement with the
results of the respiratory and oxidative-growth phenotypes
in yeast and of the greater severity of the clinical pheno-
type in individuals 1 and 2 versus that of individual 3.
The function of MTO1 could explain the variability of
the biochemical defects, ranging from isolated CI defi-
ciency, as in Pt2 fibroblasts, to combined CI-CIV deficiency
in Pt2 and Pt3 skeletal muscle, or to combined CIII-CIV
deficiency in Pt1 fibroblasts. Among the 13 mtDNA-
encoded proteins, seven are subunits of CI, three of CIV,
two of CV, and one of CIII. This gene distribution can
explain why mtDNA translation defects such as those
associated with mutations of MTO1 can predominantly
impair the activity of CI, but also that of CIII and CIV.
The two mtDNA-encoded subunits of CV are part of the
F0 component of this complex, the function of which is
not directly measured by the standard CV assay that is
based on ATP-hydrolysis, a function carried out by the F1
component of CV. This could explain, at least in part,
why CV activity was essentially normal in MTO1 mutant
samples.
The presence of a FAD moiety in MTO1 opens the
possibility that, as observed for other mitochondrial
flavo-enzymes,1,3,20 riboflavin supplementation may be
beneficial for correction, at least in part, of the biochemical8, 2012
Figure 4. PR and PS Yeast Phenotypes
(A) Spot assay of mto1D PR and PS strains, transformed with MTO1WT recombinant vector, (empty) vector, and mto1Ala431Thrand
mto1Pro622* recombinant vectors. The assay was performed by spotting decreasing concentrations of yeast cells (105, 104, 103, and 102)
on a medium supplemented with either 2% glucose (upper panel) or 2% glycerol (lower panel). See text for details.
(B) Respiratory activity of yeastMTO1WTandmutant PR strains at 28C. Respiratory rates were normalized to theWTstrain, for which the
respiratory rate was 26.6 nmol min1 mg1. Values are the mean of at least four independent experiments. Two-tail, unpaired t test was
applied for statistical significance. *: p < 0.05; **p < 0.01; ***: p < 0.001.
Data are represented as mean5 SD.defect and improvement of the clinical course. However,
we observed neither correction of MRC biochemical activ-
ities (Table 1) nor improvement of oxygen consumption
(data not shown) by growing Pt1 and Pt2 mutant fibro-
blasts in 5.3 mM riboflavin for 1 week. Likewise, addition
of different amounts of riboflavin (0.53, 2.6, 5.3, 13.3,
and 26.6 mM) to a glycerol medium had no effect on either
growth or respiration of mto1 mutant yeast strains (data
not shown). These results indicate that riboflavin supple-
mentation is ineffective, possibly because the truncating
mutation is too drastic and the missense mutation does
not affect the N-terminal, FAD-binding domain of the
protein.21
An additional source of complexity stems from the exis-
tence of transcript variants encoding at least three different
MTO1 isoforms. Although isoform a is prevalent, being in
fact the only one that we could detect in fibroblasts, the
presence of isoforms b (NM_133645, NP_598400) and
c (NM_001123226, NP_001116698) is also predicted,
each retaining a different extra-exon resulting in proteinThe Americsequences longer than those of isoform a.22 The existence
and functional significance of these longer variants are
presently unknown. Notably, both mutations found in
this study affect the protein sequence common to all three
isoforms, predicting overall impairment of the MTO1
function.
MTO1 and MTO2 (TRMU) take part in the same
pathway involved in posttranscriptional modification of
specific mt-tRNAs.10 Interestingly, specific TRMU muta-
tions cause severe and sometimes fatal liver failure (MIM
613070),23 and other mutations in the same gene have
been associated with reversible mitochondrial myop-
athy.24 Here we report mutations of MTO1 associated
with impairment of yet another target organ, the heart,
the severity of which seems to depend on the potential
deleteriousness of the mutations. The mechanisms under-
lying such diverse tissue and organ specificity in the same
enzyme or in the same enzymatic pathway is a challenge
for future work in this rapidly expanding field of mito-
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Figure 5. In-Vivo Mitochondrial Translation of PR mto1D Strain
Transformed with WT or Mutant MTO1 Alleles
Mitochondrial gene products were labeled with [35S] methionine
in whole cells at 30C in the presence of cycloheximide for
7 min.19 Equivalent amounts of total cellular proteins were
separated by SDS-PAGE on a 17.5% polyacrylamide gel, transferred
to a nitrocellulose membrane, and exposed to X-ray film.
The mto1D strain transformed with the empty vector (vector)
contained 40% of petite cells, thus reducing the overall signal.
Cox: cytochrome c oxidase; Cob: cytochrome b; Atp: ATP syn-
thase; Var1: small mitochondrial ribosome subunit. In the
mto1Pro622* strain, several bands, particularly Cox1, Cox2, and
Cob, are virtually missing, and the overall pattern is similar to
that of the (empty) vector. In the mto1Ala431Thr, the intensity of
some bands, including Var1 and Atp6, is slightly reduced
compared to the MTO1WT strain, but the two patterns are similar,
suggesting mild impairment.Supplemental Data
Supplemental Data include four figures and two tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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